CLAIMS

1. The use of a composition comprising a therapeutically effective amount of a compound of Formula (I) for the manufacture of a medicament for treating cataplexy,
wherein the cataplexy is associated with narcolepsy:



(I)

or a pharmaceutically acceptable salt thereof;
wherein R is a member selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, halogen selected from F, Cl, Br and I, alkoxy containing 1 to 3 carbon atoms, nitro, hydroxy, trifluoromethyl, and thioalkoxy containing 1 to 3 carbon atoms;
x is an integer of 0 to 3, with the proviso that R may be the same or different when x is 2 or 3;
R_1 and R_2 are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, arylalkyl, cycloalkyl of 3 to 7 carbon atoms; or
R_1 and R_2 can be joined to form a 5 to 7-membered heterocycle substituted with a member selected from the group consisting of hydrogen, alkyl, and aryl groups, wherein the heterocycle can comprise 1 to 2 nitrogen atoms and 0 to 1 oxygen atom, wherein the nitrogen atoms are not directly connected with each other or with the oxygen atom.

2. The use of claim 1, wherein x = 0.

3. The use of claim 1, wherein R_1 and R_2 are hydrogen and x = 0.

4. The use of any one of claims 1-3, wherein the compound of Formula I is an enantiomer of Formula I substantially free of other enantiomers or an enantiomeric mixture wherein one enantiomer of Formula I predominates.

5. The use of claim 4, wherein the enantiomer of Formula I predominates to the extent of 90% or greater.

6. The use of claim 4, wherein the enantiomer of Formula I predominates to the extent of 98% or greater.

7. The use of claim 4, wherein the enantiomer of Formula I is an enantiomer of Formula Ia:

○○○○



(Ia)

or a pharmaceutically acceptable salt thereof.

8. The use of claim 7, wherein the enantiomer of Formula Ia is the (R) enantiomer.

9. The use of claim 7, wherein the enantiomer of Formula Ia is the (S) enantiomer.

10. The use of claim 7, wherein the enantiomer of Formula Ia predominates to the extent of 90% or greater.

11. The use of claim 7, wherein the enantiomer of Formula Ia predominates to the extent of 98% or greater.

12. The use of claim 4, wherein the enantiomer of Formula I substantially free of other enantiomers is the compound of Formula Ib or an enantiomeric mixture wherein the compound of Formula Ib predominates:



(Ib)

or a pharmaceutically acceptable salt thereof.

13. The use of claim 12, wherein the compound of Formula Ib predominates to the extent of 90% or greater.

14. The use of claim 12, wherein the compound of Formula Ib predominates to the extent of 98% or greater.

15. The use of any one of claims 1-14, wherein the therapeutically effective amount of the compound of Formula I is from 0.01 mg/kg/dose to 150 mg/kg/dose.

16. The use of any one of claims 1-14, wherein the therapeutically effective amount of the compound of Formula I is from 1 mg/day to 7000 mg/day.

17. The use of any one of claims 1-16, wherein the composition is in the form of a capsule or tablet.